These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30230699)

  • 1. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
    Fan J; Fong T; Xia Z; Zhang J; Luo P
    Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M; Shao T; Shao H; Zhou C; Tang W
    BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
    Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
    Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review.
    Zhao X; Feng Z; Wang G; Pang H; Wang M
    Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
    Li H; Lai L; Wu B
    Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
    Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
    PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.
    Zhu Q; Hu H; Weng DS; Zhang XF; Chen CL; Zhou ZQ; Tang Y; Xia JC
    BMC Cancer; 2017 Jun; 17(1):412. PubMed ID: 28606126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
    Hida T; Seto T; Horinouchi H; Maemondo M; Takeda M; Hotta K; Hirai F; Kim YH; Matsumoto S; Ito M; Ayukawa K; Tokushige K; Yonemura M; Mitsudomi T; Nishio M
    Cancer Sci; 2018 Sep; 109(9):2863-2872. PubMed ID: 29959809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
    Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
    Huang SH; Huang AC; Wang CC; Chang WC; Liu CY; Pavlidis S; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2019 Dec; 10(12):2274-2281. PubMed ID: 31613427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
    Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
    Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
    Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
    Gadgeel S; Peters S; Mok T; Shaw AT; Kim DW; Ou SI; Pérol M; Wrona A; Novello S; Rosell R; Zeaiter A; Liu T; Nüesch E; Balas B; Camidge DR
    Ann Oncol; 2018 Nov; 29(11):2214-2222. PubMed ID: 30215676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.